BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Bruha R, Jachymova M, Petrtyl J, Dvorak K, Lenicek M, Urbanek P, Svestka T, Vitek L. Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis. World J Gastroenterol 2016; 22(12): 3441-3450 [PMID: 27022226 DOI: 10.3748/wjg.v22.i12.3441]
URL: https://www.wjgnet.com/1007-9327/full/v22/i12/3441.htm
Number Citing Articles
1
Radan Bruha. Biomarkers in Liver DiseaseBiomarkers in Disease: Methods, Discoveries and Applications 2016; : 1 doi: 10.1007/978-94-007-7742-2_44-1
2
Severin Donald Kamdem, Roger Moyou-Somo, Frank Brombacher, Justin Komguep Nono. Host Regulators of Liver Fibrosis During Human SchistosomiasisFrontiers in Immunology 2018; 9 doi: 10.3389/fimmu.2018.02781
3
Élise Vuille-Lessard, Susana G. Rodrigues, Annalisa Berzigotti. Noninvasive Detection of Clinically Significant Portal Hypertension in Compensated Advanced Chronic Liver DiseaseClinics in Liver Disease 2021; 25(2): 253 doi: 10.1016/j.cld.2021.01.005
4
Radan Bruha, Libor Vitek, Vaclav Smid. Osteopontin – A potential biomarker of advanced liver diseaseAnnals of Hepatology 2020; 19(4): 344 doi: 10.1016/j.aohep.2020.01.001
5
Jonathan Chung-Fai Leung, Thomson Chi-Wang Loong, James Pang, Jeremy Lok Wei, Vincent Wai-Sun Wong. Invasive and non-invasive assessment of portal hypertensionHepatology International 2018; 12(S1): 44 doi: 10.1007/s12072-017-9795-0
6
Ramesh Rana, Shenglan Wang, Jing Li, Shiva Basnet, Liang Zheng, Changqing Yang. Diagnostic accuracy of non-invasive methods detecting clinically significant portal hypertension in liver cirrhosis: a systematic review and meta-analysisMinerva Medica 2020; 111(3) doi: 10.23736/S0026-4806.19.06143-3
7
Radan Bruha. Biomarkers in Liver DiseaseBiomarkers in Disease: Methods, Discoveries and Applications 2017; : 427 doi: 10.1007/978-94-007-7675-3_44
8
Dmitry Victorovich Garbuzenko, Nikolay Olegovich Arefyev. Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis: An update and review of the literatureJournal of Evidence-Based Medicine 2020; 13(4): 313 doi: 10.1111/jebm.12407
9
Xiaolong Qi, Annalisa Berzigotti, Andres Cardenas, Shiv Kumar Sarin. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertensionThe Lancet Gastroenterology & Hepatology 2018; 3(10): 708 doi: 10.1016/S2468-1253(18)30232-2
10
Gyorgy Baffy. Origins of Portal Hypertension in Nonalcoholic Fatty Liver DiseaseDigestive Diseases and Sciences 2018; 63(3): 563 doi: 10.1007/s10620-017-4903-5
11
Sona Frankova, Mariia Lunova, Halima Gottfriedova, Renata Senkerikova, Magdalena Neroldova, Jozef Kovac, Eva Kieslichova, Vera Lanska, Petr Urbanek, Julius Spicak, Milan Jirsa, Jan Sperl, Pavel Strnad. Liver stiffness measured by two-dimensional shear-wave elastography predicts hepatic vein pressure gradient at high values in liver transplant candidates with advanced liver cirrhosisPLOS ONE 2021; 16(1): e0244934 doi: 10.1371/journal.pone.0244934
12
Fabian Benz, Andreas Bogen, Michael Praktiknjo, Christian Jansen, Carsten Meyer, Alexander Wree, Muenevver Demir, Sven Loosen, Mihael Vucur, Robert Schierwagen, Frank Tacke, Jonel Trebicka, Christoph Roderburg, Pavel Strnad. Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosisPLOS ONE 2020; 15(4): e0231701 doi: 10.1371/journal.pone.0231701
13
Jie Dong, Qiang Ma. Osteopontin enhances multi-walled carbon nanotube-triggered lung fibrosis by promoting TGF-β1 activation and myofibroblast differentiationParticle and Fibre Toxicology 2017; 14(1) doi: 10.1186/s12989-017-0198-0